Anomalous Magnetic Dipole Moment (g−2)μ(g-2)\mu in 3-3-1 Model with Inverse Seesaw Neutrinos

We will show that the recent experimental value of the anomalous magnetic moment (AMM) of the charged lepton m , denoted as $a_mu (g-2)\mu/2$, can be explained successfully in a 3-3-1 model with right handed neutrino adding new heavy $SU (3)_L$ neutrinos singlets. Allowed regions satisfying the recent AMM data are illustrated numerically

Production Cross Sections of Axion in a Static Electromagnetic Field

Photon - axion conversions in staticelectromagnetic fields of the size $a\times b \times c$ areconsidered in detail by the Feynman diagram methods. Thedifferential cross sections are presented and the numericalevaluations of the total cross section are given. Our result showsthat the conversion cross-sections in the electric field are quitesmall, while in the strong magnetic field, the cross-sections are much enhanced, which can be measurable in current experiments.Photon - axion conversions in staticelectromagnetic fields of the size $a\times b \times c$ areconsidered in detail by the Feynman diagram methods. The differential cross sections are presented and the numerical evaluations of the total cross section are given. Our result shows that the conversion cross-sections in the electric field are quite small, while in the strong magnetic field, the cross-sections are much enhanced, which can be measurable in current experiments

Axion in a 3-3-1 Model with Right-handed Neutrinos

We  show that Peccei - Quinn(PQ) symmetry can be a natural outcomein the 3-3-1 model with right neutrinos after imposing a$Z_{11}\bigotimes Z_{2}$ symmetry. This symmetry is suitableaccommodated in this model when we augmented its spectrum byincluding a singlet scalar field with large VEV. After breakingthe PQ symmetry yielding the axion we study the decay of axioninto two photons. The result shows that the lifetime of axion isvery long, therefore the axion can play the role of the latedecaying particle(LDP) in a dark matter and it is stable in ouruniverse

Study on the effect of processing methods on the total polyphenol, 2,3,5,4’-tetrahydroxystilben-2-O-β-D-glucoside, and physcion contents in Fallopia multiflora Thunb. Haraldson root

This study investigated the changes in the ingredients in Fallopia multiflora Thunb. Haraldson (FMT) root after processing it with different methods such as soaking, stewing, and steaming or combined methods. The total polyphenol, 2,3,5,4′-tetrahydroxystilben-2-O-β-D-glucoside (THSG), and physcion contents in FMT products after processing were determined using high-performance liquid chromatography (HPLC) and ultraviolet-visible (UV-VIS) methods. The results demonstrated that the processing method and time significantly affected the contents of polyphenol, THSG, and physcion. The physcion and total polyphenol content increased or decreased during processing depending upon the processing time, while the THSG content gradually decreased with an increase in the processing time. The content of physcion (a substance that can cause liver toxicity) was analysed, and the suitable conditions for processing of the FMT products were determined as initial soaking in rice swill for 24 h and subsequent stewing with black beans and water for 12 h

GENETIC PARAMETERS OF FIELD SURVIVAL IN STRIPED CATFISH (Pangasianodon hypophthalmus)

Grow-out or field survival (GS) is one of the most important traits of striped catfish. Genetic parameters of GS in generation 4 of the growth selected population of this species were estimated based on the data of 8,004 tagged and stocked and 6,410 harvested fish representing 152 full-sib and half-sib families. The heritability and estimated and realized correlated responses for GS, its phenotypic or genetic correlations with harvest weight (HW) and other growth traits, and direct realized response for HW were calculated. The low and significantly different from zero heritability for GS (0.12±0.05) was estimated. The medium positive and no significant difference from zero genetic correlation between GS and HW was found, 0.41±0.24. The estimated selection responses with the proposed selection proportion of 13.0% for GS was 8.5% in trait unit. Current and accumulated correlated selection responses for GS were -7.8% and -1.6%, and 25.5% and 47.6%, respectively, by Estimated Breeding Value and Least Square Means estimation methods. In addition to these results, the high heritability and direct estimated and realized responses for HW pose a great potential for applying multi-trait selection, including both GS and HW in G4 and in the long run

Protective and Enhancing HLA Alleles, HLA-DRB1*0901 and HLA-A*24, for Severe Forms of Dengue Virus Infection, Dengue Hemorrhagic Fever and Dengue Shock Syndrome

Dengue has become one of the most common viral diseases transmitted by infected mosquitoes (with any of the four dengue virus serotypes: DEN-1, -2, -3, or -4). It may present as asymptomatic or illness, ranging from mild to severe disease. Recently, the severe forms, dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), have become the leading cause of death among children in Southern Vietnam. The pathogenesis of DHF/DSS, however, is not yet completely understood. The immune response, virus virulence, and host genetic background are considered to be risk factors contributing to disease severity. Human leucocyte antigens (HLA) expressed on the cell surface function as antigen presenting molecules and those polymorphism can change individuals' immune response. We investigated the HLA-A, -B (class I), and -DRB1 (class II) polymorphism in Vietnamese children with different severity (DHF/DSS) by a hospital-based case-control study. The study showed persons carrying HLA-A*2402/03/10 are about 2 times more likely to have severe dengue infection than others. On the other hand, HLA-DRB1*0901 persons are less likely to develop DSS with DEN-2 virus infection. These results clearly demonstrated that HLA controlled the susceptibility to severe forms of DV infection

Association of mast cell-derived VEGF and proteases in dengue shock syndrome

Background: Recent in-vitro studies have suggested that mast cells are involved in Dengue virus infection. To clarify the role of mast cells in the development of clinical Dengue fever, we compared the plasma levels of several mast cell-derived mediators (vascular endothelial cell growth factor [VEGF], soluble VEGF receptors [sVEGFRs], tryptase, and chymase) and -related cytokines (IL-4, -9, and -17) between patients with differing severity of Dengue fever and healthy controls. Methodology/Principal Findings: The study was performed at Children\u27s Hospital No. 2, Ho Chi Minh City, and Vinh Long Province Hospital, Vietnam from 2002 to 2005. Study patients included 103 with Dengue fever (DF), Dengue hemorrhagic fever (DHF), and Dengue shock syndrome (DSS), as diagnosed by the World Health Organization criteria. There were 189 healthy subjects, and 19 febrile illness patients of the same Kinh ethnicity. The levels of mast cell-derived mediators and -related cytokines in plasma were measured by ELISA. VEGF and sVEGFR-1 levels were significantly increased in DHF and DSS compared with those of DF and controls, whereas sVEGFR-2 levels were significantly decreased in DHF and DSS. Significant increases in tryptase and chymase levels, which were accompanied by high IL-9 and -17 concentrations, were detected in DHF and DSS patients. By day 4 of admission, VEGF, sVEGFRs, and proteases levels had returned to similar levels as DF and controls. In-vitro VEGF production by mast cells was examined in KU812 and HMC-1 cells, and was found to be highest when the cells were inoculated with Dengue virus and human Dengue virus-immune serum in the presence of IL-9. Conclusions: As mast cells are an important source of VEGF, tryptase, and chymase, our findings suggest that mast cell activation and mast cell-derived mediators participate in the development of DHF. The two proteases, particularly chymase, might serve as good predictive markers of Dengue disease severity

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke